AU2012262534B2 - Method of determining vasoreactivity using inhaled nitric oxide - Google Patents
Method of determining vasoreactivity using inhaled nitric oxide Download PDFInfo
- Publication number
- AU2012262534B2 AU2012262534B2 AU2012262534A AU2012262534A AU2012262534B2 AU 2012262534 B2 AU2012262534 B2 AU 2012262534B2 AU 2012262534 A AU2012262534 A AU 2012262534A AU 2012262534 A AU2012262534 A AU 2012262534A AU 2012262534 B2 AU2012262534 B2 AU 2012262534B2
- Authority
- AU
- Australia
- Prior art keywords
- patient
- vasoactive agent
- hemodynamics
- indicator
- pulmonary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 59
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title claims description 257
- 210000005241 right ventricle Anatomy 0.000 claims abstract description 69
- 229940127293 prostanoid Drugs 0.000 claims abstract description 51
- 150000003814 prostanoids Chemical class 0.000 claims abstract description 51
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims abstract description 46
- 208000008166 Right Ventricular Dysfunction Diseases 0.000 claims abstract description 39
- 230000006814 right ventricular dysfunction Effects 0.000 claims abstract description 39
- 230000000004 hemodynamic effect Effects 0.000 claims description 116
- 239000002550 vasoactive agent Substances 0.000 claims description 90
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 claims description 83
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 83
- 230000036593 pulmonary vascular resistance Effects 0.000 claims description 78
- 230000000747 cardiac effect Effects 0.000 claims description 74
- 230000007423 decrease Effects 0.000 claims description 74
- 238000012544 monitoring process Methods 0.000 claims description 73
- 239000003638 chemical reducing agent Substances 0.000 claims description 71
- 239000011149 active material Substances 0.000 claims description 55
- 230000002685 pulmonary effect Effects 0.000 claims description 37
- 239000003071 vasodilator agent Substances 0.000 claims description 29
- 229940124549 vasodilator Drugs 0.000 claims description 28
- 230000004044 response Effects 0.000 claims description 24
- 230000008859 change Effects 0.000 claims description 23
- 230000004872 arterial blood pressure Effects 0.000 claims description 20
- 230000001154 acute effect Effects 0.000 claims description 19
- 239000003963 antioxidant agent Substances 0.000 description 67
- 230000003078 antioxidant effect Effects 0.000 description 67
- 235000006708 antioxidants Nutrition 0.000 description 67
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 44
- 238000002560 therapeutic procedure Methods 0.000 description 42
- 229960001123 epoprostenol Drugs 0.000 description 33
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 33
- 230000007704 transition Effects 0.000 description 22
- 239000007864 aqueous solution Substances 0.000 description 21
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 20
- 235000010323 ascorbic acid Nutrition 0.000 description 20
- 239000011668 ascorbic acid Substances 0.000 description 20
- 229960005070 ascorbic acid Drugs 0.000 description 20
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 20
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- -1 trepostinil Chemical compound 0.000 description 14
- 239000007789 gas Substances 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 10
- 108010024636 Glutathione Proteins 0.000 description 10
- 229940087168 alpha tocopherol Drugs 0.000 description 10
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 10
- 235000010382 gamma-tocopherol Nutrition 0.000 description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 10
- 229960003180 glutathione Drugs 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 150000002826 nitrites Chemical class 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 150000003573 thiols Chemical class 0.000 description 10
- 229960000984 tocofersolan Drugs 0.000 description 10
- 235000004835 α-tocopherol Nutrition 0.000 description 10
- 239000002076 α-tocopherol Substances 0.000 description 10
- 239000002478 γ-tocopherol Substances 0.000 description 10
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 9
- 210000005166 vasculature Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 230000004087 circulation Effects 0.000 description 8
- 238000007726 management method Methods 0.000 description 8
- 150000003180 prostaglandins Chemical class 0.000 description 8
- 238000012552 review Methods 0.000 description 8
- 206010019280 Heart failures Diseases 0.000 description 7
- 238000010606 normalization Methods 0.000 description 7
- 239000012047 saturated solution Substances 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000002664 inhalation therapy Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 150000003815 prostacyclins Chemical class 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000024883 vasodilation Effects 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000000949 Cochran's Q test Methods 0.000 description 4
- 238000000729 Fisher's exact test Methods 0.000 description 4
- 238000001135 Friedman test Methods 0.000 description 4
- 238000001265 Jonckheere trend test Methods 0.000 description 4
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 4
- 238000012313 Kruskal-Wallis test Methods 0.000 description 4
- 238000000585 Mann–Whitney U test Methods 0.000 description 4
- 238000001347 McNemar's test Methods 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 238000001787 Wald–Wolfowitz test Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000000546 chi-square test Methods 0.000 description 4
- 229960002240 iloprost Drugs 0.000 description 4
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 210000001147 pulmonary artery Anatomy 0.000 description 4
- 208000002815 pulmonary hypertension Diseases 0.000 description 4
- 238000001629 sign test Methods 0.000 description 4
- 238000000528 statistical test Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 4
- 230000002227 vasoactive effect Effects 0.000 description 4
- 206010059865 Jugular vein distension Diseases 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000002592 echocardiography Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010013012 Dilatation ventricular Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008570 general process Effects 0.000 description 2
- 239000011491 glass wool Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000011947 six minute walk test Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 200000000007 Arterial disease Diseases 0.000 description 1
- 206010007560 Cardiac failure high output Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000032840 Catheter-Related Infections Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010069802 Device related sepsis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 208000006148 High Cardiac Output Diseases 0.000 description 1
- 101000605431 Mus musculus Phospholipid phosphatase 1 Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010033433 Pain in jaw Diseases 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019271 high output heart failure Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 230000008704 pulmonary vasodilation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 230000004865 vascular response Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000001467 vasoreactive effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/026—Measuring blood flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Surgery (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Physiology (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490929P | 2011-05-27 | 2011-05-27 | |
| US61/490,929 | 2011-05-27 | ||
| PCT/US2012/039401 WO2012166534A1 (en) | 2011-05-27 | 2012-05-24 | Method of determining vasoreactivity using inhaled nitric oxide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2012262534A1 AU2012262534A1 (en) | 2013-12-12 |
| AU2012262534B2 true AU2012262534B2 (en) | 2016-06-02 |
Family
ID=47259769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012262534A Ceased AU2012262534B2 (en) | 2011-05-27 | 2012-05-24 | Method of determining vasoreactivity using inhaled nitric oxide |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11154210B2 (enExample) |
| EP (1) | EP2713723B1 (enExample) |
| JP (3) | JP2014527025A (enExample) |
| AU (1) | AU2012262534B2 (enExample) |
| CA (1) | CA2837341C (enExample) |
| WO (1) | WO2012166534A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7618594B2 (en) | 2004-08-18 | 2009-11-17 | Geno Llc | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
| EP2724742B1 (en) * | 2004-08-18 | 2017-11-01 | Geno LLC | Conversion of nitrogen dioxide (no2) to nitric oxide (no) |
| WO2009097343A1 (en) | 2008-01-28 | 2009-08-06 | Geno Llc | Conversion of nitrogen dioxide (no2) to nitric oxide (no) |
| US8607785B2 (en) | 2008-08-21 | 2013-12-17 | Geno Llc | Systems and devices for generating nitric oxide |
| WO2010151505A1 (en) | 2009-06-22 | 2010-12-29 | Geno Llc | Nitric oxide therapies |
| CA2837341C (en) | 2011-05-27 | 2021-10-19 | Geno Llc | Method of determining vasoreactivity using inhaled nitric oxide |
| EP2951968B1 (en) | 2014-04-15 | 2018-07-18 | CommScope Technologies LLC | Wideband remote unit for distributed antenna system |
| AU2017218391B2 (en) * | 2016-02-12 | 2022-11-24 | Mallinckrodt Pharmaceuticals Ireland Limited | Use and monitoring of inhaled nitric oxide with left ventricular assist devices |
| WO2018157172A1 (en) | 2017-02-27 | 2018-08-30 | Third Pole, Inc. | Systems and methods for generating nitric oxide |
| US10328228B2 (en) | 2017-02-27 | 2019-06-25 | Third Pole, Inc. | Systems and methods for ambulatory generation of nitric oxide |
| MX2020010523A (es) | 2017-02-27 | 2021-02-09 | Third Pole Inc | Sistemas y metodos para generar oxido nitrico. |
| US11672938B1 (en) | 2018-07-18 | 2023-06-13 | Vero Biotech LLC | Start-up protocols for nitric oxide delivery device |
| CA3116166A1 (en) * | 2018-10-12 | 2020-04-16 | Sanotize Research And Development Corp. | Gas-evolving compositions and container and delivery systems |
| JP2022533628A (ja) | 2019-05-15 | 2022-07-25 | サード ポール，インコーポレイテッド | 一酸化窒素生成用電極 |
| US11479464B2 (en) | 2019-05-15 | 2022-10-25 | Third Pole, Inc. | Systems and methods for generating nitric oxide |
| WO2020232414A1 (en) | 2019-05-15 | 2020-11-19 | Third Pole, Inc. | Architectures for production of nitric oxide |
| EP4069069A4 (en) | 2020-01-11 | 2024-07-03 | Third Pole, Inc. | SYSTEMS AND METHODS FOR NITROGEN OXIDE PRODUCTION WITH HUMIDITY CONTROL |
| EP4167920A4 (en) | 2020-06-18 | 2024-06-12 | Third Pole, Inc. | Systems and methods for preventing and treating infections with nitric oxide |
| WO2022082072A1 (en) | 2020-10-16 | 2022-04-21 | Third Pole, Inc. | Nitric oxide generation process controls |
| US11975139B2 (en) | 2021-09-23 | 2024-05-07 | Third Pole, Inc. | Systems and methods for delivering nitric oxide |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006063215A2 (en) * | 2004-12-08 | 2006-06-15 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| WO2011002606A1 (en) * | 2009-06-30 | 2011-01-06 | Ikaria Holdings, Inc. | Methods of identifying a patient population eligible for treatment with nitric oxide via inhalation |
| WO2012075420A1 (en) * | 2010-12-03 | 2012-06-07 | Geno Llc | Nitric oxide treatments |
| WO2012151701A1 (en) * | 2011-05-10 | 2012-11-15 | Université Laval / Vice-Rectorat À La Recherche Et À La Création | Methods for the treatment and diagnostic of pulmonary arterial hypertension |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6758214B2 (en) | 2000-01-28 | 2004-07-06 | Cyterra Corporation | Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment |
| CA2459891C (en) | 2001-09-05 | 2014-02-04 | Cyterra Corporation | Method and apparatus for nitric oxide generation |
| US7618594B2 (en) | 2004-08-18 | 2009-11-17 | Geno Llc | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
| EP2724742B1 (en) | 2004-08-18 | 2017-11-01 | Geno LLC | Conversion of nitrogen dioxide (no2) to nitric oxide (no) |
| WO2007087575A2 (en) * | 2006-01-24 | 2007-08-02 | University Of Chicago | Compositions and methods for treating pulmonary hypertension |
| CA2681308C (en) | 2007-03-23 | 2015-11-24 | Geno Llc | Conversion of nitrogen dioxide (no2) to nitric oxide (no) |
| WO2009097343A1 (en) | 2008-01-28 | 2009-08-06 | Geno Llc | Conversion of nitrogen dioxide (no2) to nitric oxide (no) |
| JP6058888B2 (ja) | 2008-07-24 | 2017-01-11 | ゲノ エルエルシー | 患者における心臓の病気の診断及び治療方法 |
| US10960168B2 (en) | 2008-08-21 | 2021-03-30 | Vero Biotech LLC | Delivery of high concentration nitric oxide |
| US10780241B2 (en) | 2008-08-21 | 2020-09-22 | Vero Biotech LLC | Devices and methods for minimizing and treating high-altitude sickness |
| US8607785B2 (en) | 2008-08-21 | 2013-12-17 | Geno Llc | Systems and devices for generating nitric oxide |
| US8701657B2 (en) | 2008-08-21 | 2014-04-22 | Geno Llc | Systems for generating nitric oxide |
| US8173072B2 (en) | 2008-09-22 | 2012-05-08 | Geno Llc | Conversation of nitrogen dioxide (NO2) to nitric oxide (NO) |
| WO2010151505A1 (en) | 2009-06-22 | 2010-12-29 | Geno Llc | Nitric oxide therapies |
| US20120093948A1 (en) * | 2009-11-20 | 2012-04-19 | Fine David H | Nitric Oxide Treatments |
| US8646445B2 (en) | 2009-11-20 | 2014-02-11 | Geno Llc | Nitric oxide delivery system |
| WO2011137122A1 (en) | 2010-04-26 | 2011-11-03 | Geno Llc | Nitrosyl special connector |
| WO2011137124A1 (en) | 2010-04-26 | 2011-11-03 | Geno Llc | Delivery of ultra pure nitric oxide (no) |
| USD688352S1 (en) | 2010-04-27 | 2013-08-20 | Geno Llc | Female gas connector |
| USD679366S1 (en) | 2010-04-27 | 2013-04-02 | Geno Llc | Male gas connector |
| CA2837341C (en) | 2011-05-27 | 2021-10-19 | Geno Llc | Method of determining vasoreactivity using inhaled nitric oxide |
| EP3209360B1 (en) | 2014-10-20 | 2022-12-07 | VERO Biotech LLC | Nitrogen dioxide storage cassette |
-
2012
- 2012-05-24 CA CA2837341A patent/CA2837341C/en active Active
- 2012-05-24 AU AU2012262534A patent/AU2012262534B2/en not_active Ceased
- 2012-05-24 WO PCT/US2012/039401 patent/WO2012166534A1/en not_active Ceased
- 2012-05-24 EP EP12793863.7A patent/EP2713723B1/en active Active
- 2012-05-24 JP JP2014512110A patent/JP2014527025A/ja active Pending
-
2013
- 2013-01-07 US US13/735,558 patent/US11154210B2/en active Active
-
2017
- 2017-03-27 JP JP2017061811A patent/JP2017165731A/ja not_active Ceased
-
2019
- 2019-02-28 JP JP2019035311A patent/JP2019131556A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006063215A2 (en) * | 2004-12-08 | 2006-06-15 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| WO2011002606A1 (en) * | 2009-06-30 | 2011-01-06 | Ikaria Holdings, Inc. | Methods of identifying a patient population eligible for treatment with nitric oxide via inhalation |
| WO2012075420A1 (en) * | 2010-12-03 | 2012-06-07 | Geno Llc | Nitric oxide treatments |
| WO2012151701A1 (en) * | 2011-05-10 | 2012-11-15 | Université Laval / Vice-Rectorat À La Recherche Et À La Création | Methods for the treatment and diagnostic of pulmonary arterial hypertension |
Non-Patent Citations (1)
| Title |
|---|
| Oudiz, R. et al., Advances in Pulmonary Hypertension: Official Journal of the Pulmonary Hypertension Association, 2005, vol. 4, no. 3, pages 15-25. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014527025A (ja) | 2014-10-09 |
| EP2713723A1 (en) | 2014-04-09 |
| US11154210B2 (en) | 2021-10-26 |
| CA2837341A1 (en) | 2012-12-06 |
| JP2017165731A (ja) | 2017-09-21 |
| CA2837341C (en) | 2021-10-19 |
| AU2012262534A1 (en) | 2013-12-12 |
| WO2012166534A1 (en) | 2012-12-06 |
| EP2713723A4 (en) | 2015-03-25 |
| US20130309328A1 (en) | 2013-11-21 |
| EP2713723B1 (en) | 2018-09-12 |
| JP2019131556A (ja) | 2019-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012262534B2 (en) | Method of determining vasoreactivity using inhaled nitric oxide | |
| Machado et al. | Nitric oxide and pulmonary arterial pressures in pulmonary hypertension | |
| Pijnenburg et al. | Exhaled nitric oxide in childhood asthma: a review | |
| Du et al. | Combining central venous-to-arterial partial pressure of carbon dioxide difference and central venous oxygen saturation to guide resuscitation in septic shock | |
| US20180000859A1 (en) | Systems andmethods to improve organor tissue function andorganor tissue transplant longevity | |
| Lahzami et al. | Small airways function declines after allogeneic haematopoietic stem cell transplantation | |
| Grasemann et al. | Metabolites of nitric oxide in the lower respiratory tract of children | |
| Yoon et al. | Pulmonary dysfunction is possibly a marker of malnutrition and inflammation but not mortality in patients with end-stage renal disease | |
| TW200744701A (en) | Test agent for diagnosing dyspepsia | |
| Lee-Chiong et al. | The heart in the stable COPD patient | |
| Habedank et al. | Vasodilation and exercise capacity in patients with end-stage renal disease: a prospective proof-of-concept study | |
| Portal et al. | Response to inhaled granulocyte-macrophage colony-stimulating factor in a patient with alveolar proteinosis | |
| Baur et al. | Determination of exhaled nitric oxide in respiratory diseases | |
| JP6041377B2 (ja) | 生体内活性酸素量の測定法 | |
| ÖZTUNA et al. | Effect of nasal continuous positive airway pressure on global right ventricular myocardial performance in patients with obstructive sleep apnea syndrome | |
| Morris | Pulmonary diseases | |
| Galvin et al. | Comparison of three methods for measuring cigarette smoking in patients with vascular disease | |
| Eyre et al. | MCQs and SBAs in Intensive Care Medicine | |
| Wang et al. | Lactate kinetics-oriented fluid resuscitation Strategy for lowering the application of catecholamine of septic shock in children | |
| Antonelli et al. | Year in review in Intensive Care Medicine, 2007. II. Haemodynamics, pneumonia, infections and sepsis, invasive and non-invasive mechanical ventilation, acute respiratory distress syndrome | |
| RU2413944C1 (ru) | Способ оценки тяжести острых отравлений опиоидами | |
| Shubrooks Jr et al. | Acidosis and pulmonary hemodynamics in hemorrhagic shock | |
| Kim et al. | Fractional Exhaled Nitric Oxide: Indications and Interpretation | |
| Kharitonov et al. | Exhaled nitric oxide, carbon monoxide, and breath condensate | |
| Popescu et al. | THE UTILITY OF MEASURING FENO IN MONITORING ASTHMATIC CHILDREN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| HB | Alteration of name in register |
Owner name: VERO BIOTECH LLC. Free format text: FORMER NAME(S): GENO LLC |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |